Prosperous Biopharma develops non-antibody protein drugs that mimic the high antigen-binding ability of antibody drugs, offering a novel approach to targeted therapeutics. Their computational and experimental platform significantly reduces the time and cost of discovering and generating these drug candidates. This allows them to rapidly build a portfolio of drug candidates for out-licensing or clinical trials.
Funding
Funding not disclosed
Founders
Product
Problem
The development of novel protein drugs with high antigen-binding ability is traditionally a time-consuming and expensive process, hindering the rapid creation of targeted therapeutics. Traditional methods struggle to efficiently identify and generate drug candidates with the desired specificity and efficacy.
Solution
Prosperous Biopharma is developing non-antibody protein drugs that mimic the high antigen-binding ability of antibody drugs, offering a novel approach to targeted therapeutics. The company's computational and experimental platform significantly reduces the time and cost associated with discovering and generating these drug candidates. This accelerated process enables the rapid development of a diverse portfolio of drug candidates suitable for out-licensing or entry into clinical trials. By focusing on protein and peptide-based drugs, Prosperous Biopharma aims to create therapeutics with high activity, reduced dosage requirements, and fewer side effects compared to traditional chemical drugs. The company is addressing the need for more affordable and accessible biologics, particularly in markets where the adoption of existing biologics is limited by high costs.
Target Audience
Prosperous Biopharma's primary customers are pharmaceutical companies seeking to expand their portfolios with novel, targeted protein therapeutics, as well as clinical trial organizations looking for promising drug candidates.
Features
- Computational platform for rapid identification of protein drug candidates
- Experimental platform for efficient generation and validation of drug candidates
- Focus on non-antibody protein drugs that mimic the antigen-binding ability of antibodies
- Streamlined process for building a portfolio of drug candidates
- Targeting major disease areas such as diabetes, oncology, and HIV